A Randomized Phase III Study of Adjuvant Radiotherapy Versus Adjuvant Radiochemotherapy in Patients With Incomplete ResectionThymoma or Thymic Carcinoma

Fudan University2 个研究点分布在 1 个国家目标入组 1 人2023年12月1日

适应症Thymoma and Thymic Carcinoma

干预措施radiotherapy Cisplatin Etoposide

概览

阶段: 3 期
干预措施: radiotherapy
疾病 / 适应症: Thymoma and Thymic Carcinoma
发起方: Fudan University
入组人数: 1
试验地点: 2
主要终点: Progression free survival
状态: 撤回
最后更新: 5天前

概览研究者入排标准研究组 & 干预措施结局指标研究点相似试验

概览

简要总结

This study is designed to investigate whether adjuvant radiochemotherapy after incomplete resection has a better survival than adjuvant radiotherapy for thymoma or thymic carcinoma.

详细描述

The previous trials have showed that radiotherapy was significantly associated with prolonged OS and chemotherapy is playing an increasing role in treatment of patients with thymoma or thymic carcinoma.However,whether patients with thymoma or thymic carcinoma could benefit from adjuvant radiochemotherapy after incomplete resection remains controversial. The purpose of this study is to investigate whether adjuvant radiochemotherapy after incomplete resection can improve survival for thymoma or thymic carcinoma.

注册库

clinicaltrials.gov

开始日期

2023年12月1日

结束日期

2026年12月1日

最后更新

5天前

研究类型

Interventional

研究设计

Parallel

性别

All

研究者

发起方

Fudan University

责任方

Principal Investigator

主要研究者

Kailiang Wu

professor

Fudan University

入排标准

入选标准

•18\~75 years old; Eastern Cooperative Oncology Group performance status of 0 to 2; Pathologically confirmed ; incomplete resection (R1 or R2);have adequate bone marrow, hepatic, and renal function;Patients receive incomplete resection within 3 months; Written informed consent.

排除标准

•Patients with distant metastases; Patients underwent radiotherapy or chemotherapy; Patients who have malignancy history excluding carcinoma in situ of cervix in the previous five years; Active clinical pulmonary infection; Pregnant or nursing.